Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06803823

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

A Phase 2a, Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

Sponsor: Ono Pharmaceutical Co. Ltd

Conditions Agitation Associated With Alzheimer's Disease Dementia

Interventions ONO-2020 Placebo

Updated 4 times since 2025 Last updated: Dec 16, 2025 Started: May 1, 2025 Primary completion: Dec 31, 2026 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Agitation Associated With Alzheimer's Disease Dementia and is currently actively recruiting participants. Ono Pharmaceutical Co. Ltd leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE2
Jun 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2025 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ono Pharmaceutical Co. Ltd

Data source: Ono Pharmaceutical Co. Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Akita, Japan , Aomori, Japan , Fukui, Japan , Fukuoka, Japan , Gunma, Japan , Hiroshima, Japan , Hokkaido, Japan , Kagoshima, Japan , Kanagawa, Japan and 10 more locations